After eight daunting months of battling COVID-19, there may be some light at the end of the tunnel as two potential vaccine candidates recently announced promising test results. 

Vaccines from Pfizer and Moderna are similar in that they both use emerging technology called messenger ribonucleic acid (mRNA) to reach nearly 95 percent efficacy. Typically, scientists create vaccines by using live or inactivated virus cells, which puts the actual disease into a person’s body. However, with mRNA technology, Pfizer and Moderna were able to avoid that. MRNA carries coded instructions that tell cells what defenses are necessary by appearing as a threat. 

Of Course, There's a Catch

The use of the molecule is groundbreaking for a number of reasons. One is the speed at which the vaccines were developed. The other is that the use of mRNA means the vaccines contain no infectious COVID-19 properties that could get patients sick. 

However, there is a drawback to the vaccines: they have to be stored in brutally cold temperatures.

Under normal circumstances, vaccines can survive when stored at around 40 degrees Fahrenheit, but for Moderna, the vials must be stored at -4 degrees.

For Pfizer's vaccine, the threshold for keeping an effective dose is even steeper at a staggering -94 degrees. The icy temperatures are necessary to keep the mRNA molecule intact, otherwise it “begins to fall apart and twist around in ways so that it doesn’t become effective,” a representative for the pharmaceutical giant told Cheddar.

Vaccine Storage & Distribution Roadblock

With the need for cold storage comes the obstacle of how to pull off widespread distribution. Most hospitals in the U.S. do not house facilities that meet the requirements to store either the Moderna or Pfizer vaccines for extended periods. Both vaccines are able to survive in typical storing temperatures of 35 to 46 degrees, but their shelf lives are limited that way.

For Pfizer, the vaccine would no longer be effective after five days in normal storage temperatures. Moderna, meanwhile, shows more promise when it comes to effective distribution as it’s vaccines appear to remain effective for a month while stored 35 degrees.

Pfizer has come up with a plan to ship its vaccine in boxes filled with dry ice. The vials will remain protected for up to 15 days -- but the container can only be opened up to two times per day. 

This could be a logistical nightmare for parts of the world that don't have sufficient equipment - or enough dry ice - to keep the vaccines. Even in rural America, many hospitals don't have freezers that can keep doses cold enough, particularly for the Pfizer vaccine.  

Getting Vaccinated

So what does this mean for you? Once the FDA approves emergency use authorization of either one or both of the vaccines, it looks like they will likely be distributed first among populations that need it the most: frontline healthcare workers, the elderly, and those suffering from underlying health conditions. 

Like several existing vaccinations for other conditions, both Pfizer and Moderna require two rounds of treatment in order for the body to build up complete immunity. For those receiving the Pfizer vaccine, patients will need to return for a second dose after three weeks and for those getting the Moderna vaccine, they'll have to go back for round two after four weeks. 

Video produced by Ali Larkin. Article written by Lawrence Banton.

Share:
More In Science
J&J Vaccine, Build Back Later & Love, Hate, Ate
Carlo and Baker wrap up another week discussing the latest explosion in new Covid cases in the Northeast, President Biden's stalled agenda and more. Plus, Love, Hate, Ate featuring the question: why did movie dialogue get so hard to understand?
Explaining Climate Change and Extreme Weather
From extreme cold in Texas to devastating wildfires in California to the recent tornadoes in the Midwest, the U.S. experienced a string of severe weather events in 2021. Cheddar News speaks with climate expert Sweta Chakraborty on how these disasters are linked to climate change.
How Sports Leagues Take a Lead Role in Battling COVID-19
The sports world has been at the forefront of dealing with the pandemic ever since the NBA temporarily halted operations in March 2020 and opted to play in their Florida bubble. As the omicron variant and current COVID surge forces game postponements and player quarantines, how leagues manage to continue operations through the outbreaks could be a sign of what is to come for the general public. Dr. Robby Sikka, chair of the COVID Sports Society Workgroup and a former VP with the Minnesota Timberwolves, joined Cheddar's "Closing Bell" to talk about the ways in which the NBA, NHL, and NFL are innovating amid the disruptions.
The Bump's 'Black Maternal Health' Hub Works to Reduce Black Maternal Mortality
According to the CDC, Black women are three to four times more likely to die from pregnancy-related causes than white women. The grim statistic is one of the main reasons why two organizations came together to do something. The Bump and the National Medical Association are partnering to launch The Black Maternal Health hub. The online resource will help expecting mothers feel supported, informed, and empowered throughout pregnancy and the early days of parenting. Jennifer Lee at The Bump and Dr. Rachel Villanueva, a clinical assistant professor of OB/GYN and member of the National Medical Association join Cheddar News to talk about the initiative.
Future of the Genomics Industry; Innovation in Breast Milk
On this episode of Cheddar Innovates: Nucleus CEO breaks down what the future of the genomics industry looks like; Biomilq Co-Founders explains how they are is recreating the process of milk production outside the body to combine both nutrition and practicality for new moms; A look at Curiosity Stream's 'Top Science Stories 2021.'
The Flaws and Future of the Genomics Industry
Kian Sadeghi, Founder and CEO of Nucleus, joins Cheddar Innovates to discuss how he's making genetic analysis more accessible, what our genetic code can teach us about ourselves, and what the future of the genomics industry looks like.
Load More